🧪 AACR 2026 continues to deliver — Part 2 spotlight!
3 more cutting‑edge small‑molecule breakthroughs targeting therapy  resistance, cell cycle dysregulation, and hard‑to‑treat leukemia.

🔥 Highlights:
1.ECI‑830: Highly selective CDK2 inhibitor overcoming CDK4/6
resistance in HR+/HER2‑ breast cancer.
2.CID‑078: First‑in‑class macrocyclic cell cycle inhibitor for  RB1‑deficient / E2F‑activated aggressive tumors.
3.AMX‑883: DCAF16‑dependent BRD9 degrader unlocking a new  differentiation paradigm in AML.

🤝 ChemScene powers innovation! Our high‑purity building blocks &
custom synthesis support life‑changing drug discovery from early
research to clinic.

#AACR2026 #SmallMolecule #DrugDiscovery #Proteindegradation #BuildingBlocks #Oncology #MedicinalChemistry #CustomSynthesis #ChemScene

Originally posted on LinkedIn: 2026-05-09 (UTC; date derived from the LinkedIn activity ID).

Source: ChemScene on LinkedIn